19216-56-9

Basic information

• Product Name: Prazosin
• Synonyms: 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-piperazin;1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine;1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine.;1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-piperazin;2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline;4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-quinazolin;furazosin;PRAZOSIN
• CAS NO: 19216-56-9
• Molecular Formula: C₁₉H₂₁N₅O₄
• Molecular Weight: 383.4
• EINECS: 242-885-8
• Mol File: 19216-56-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: 278-280°C
• Boiling Point: 510.33°C (rough estimate)
• Flash Point: 339.871 °C
• Appearance: /
• Density: 1.3275 (rough estimate)
• Vapor Pressure: 3.4E-16mmHg at 25°C
• Refractive Index: 1.7600 (estimate)
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: pKa 6.54(50% EtOH) (Uncertain)
• Water Solubility: 3.2mg/L(22.5 oC)
• CAS DataBase Reference: Prazosin(CAS DataBase Reference)
• NIST Chemistry Reference: Prazosin(19216-56-9)
• EPA Substance Registry System: Prazosin(19216-56-9)

Safety Data

• Hazardous Substances Data: 19216-56-9(Hazardous Substances Data)

Usage

Originator

Hypovase, Pfizer, UK,1974

Uses

Different sources of media describe the Uses of 19216-56-9 differently. You can refer to the following data:
1. Antihypertensive.
2. Prazosin is used for treating mid-to-moderate hypertension. When using this drug, blood pressure is reduced without any significant change in indicators of cardiac function such as frequency, coronary flow, or cardiac output.
3. Prazosin is used to treat average or moderate hypertension. Upon taking this drug, blood pressure drops without substantial changes in indicators of heart work, such as rate, coronary flow, and cardiac output. Prazosin is used for weak to moderate hypertension.

Definition

ChEBI: A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Manufacturing Process

Preparation of 2-Chloro-4-Amino-6,7-Dimethoxyquinazoline: To 800 ml of a solution of anhydrous ammonia in tetrahydrofuran at room temperature is added 30 g of 2,4-dichloro-6,7-dimethoxyquinazoline [F.H.S. Curd et al., J. Chem. Soc., p 1759 (1948)]. The mixture is stirred for 44 hours. The precipitate (29 g, MP 267° to 268°C) is filtered and recrystallized from methanol to yield 19 g of 2-chloro-4-amino-6,7-dimethoxyquinazoline, MP 302°C (dec.).Preparation of 2-(1-Piperazinyl)-4-Amino-6,7-Dimethoxyquinazoline: To 5 g of 2-chloro-4-amino-6,7-dimethoxyquinazoline, is added 20 g of a 25% solution of piperazine in ethanol. The mixture is heated at 160°C for 16 hours in a pressure bottle. The solvent is then evaporated and the residue is recrystallized from methanol/water.Preparation of 2[4-(2-Furoyl)-Piperazinyl]-4-Amino-6,7-Dimethoxyquinazoline: To 0.10 mol 2-(1-piperazinyl)-4-amino-6,7-dimethoxyquinazoline in 300 ml methanol is added with vigorous stirring, 0.10 mol 2-furoyl chloride. After addition is complete, the mixture is stirred for 3 hours at room temperature. The solids are filtered to give the desired product, MP 278° to 280°C.

Brand name

Minipress (Pfizer).

Therapeutic Function

Antihypertensive

Clinical Use

Prazosin is effective in reducing all grades of hypertension. The drug can be administered alone in mild and (in some instances) moderate hypertension.When the hypertension is moderate or severe, prazosin generally is given in combination with a thiazide diuretic and a -blocker. The antihypertensive actions of prazosin are considerably potentiated by coadministration of thiazides or other types of antihypertensive drugs. Prazosin may be particularly useful when patients cannot tolerate other classes of antihypertensive drugs or when blood pressure is not well controlled by other drugs. Since prazosin does not significantly influence blood uric acid or glucose levels, it can be used in hypertensive patients whose condition is complicated by diabetes mellitus or gout. Prazosin and other -antagonists find use in the management of benign prostatic obstruction, especially in patients who are not candidates for surgery. Blockade of -adrenoceptors in the base of the bladder and in the prostate apparently reduces the symptoms of obstruction and the urinary urgency that occurs at night.

Side effects

Although less of a problem than with phenoxybenzamine or phentolamine, symptoms of postural hypotension, such as dizziness and light-headedness, are the most commonly reported side effects associated with prazosin therapy. These effects occur most frequently during initial treatment and when the dosage is sharply increased. Postural hypotension seems to be more pronounced during Na deficiency, as may occur in patients on a low-salt diet or being treated with diuretics, - blockers, or both.

Synthesis

Prazosin, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-piperazine (12.2.12), is synthesized from 2-amino-4,5-dimethoxybenzoic acid, which upon reaction with sodium cyanate undergoes heterocyclation into 2,4-dihydroxy-6,7-dimethoxyquinazoline (12.2.9). Substituting hydroxyl groups of this compound with chlorine atoms by reaction with thionyl chloride, or a mixture of phosphorous oxychloride with phosphorous pentachloride gives 2,4-dichloro-6,7-dimethoxyquinazoline (12.2.10). Upon subsequent reaction with ammonia, the chlorine atom at C4 of the pyrimidine ring is replaced with an amino group, which leads to the formation of 4-amino-2-chloro-6,7-dimethoxyquinazoline (12.2.11). Introducing this into a reaction with 1-(2-furoyl)piperazine gives prazosin (12.2.12) [38–47].

Veterinary Drugs and Treatments

Prazosin is less well studied in dogs than hydralazine, and its capsule dosage form makes it less convenient for dosing. Prazosin, however, appears to have fewer problems with causing tachycardia, and its venous dilation effects may be an advantage over hydralazine when preload reduction is desired. It could be considered for therapy for the adjunctive treatment of CHF, particularly when secondary to mitral or aortic valve insufficiency when hydralazine is ineffective or not tolerated. Prazosin may also be used for the treatment of systemic hypertension or pulmonary hypertension in dogs.

Drug interactions

Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Antidepressants: enhanced hypotensive effect with MAOIs. Avanafil, vardenafil, sildenafil and tadalafil: enhanced hypotensive effect - avoid. Beta-blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect. Calcium-channel blockers: enhanced hypotensive effect, increased risk of first dose hypotensive effect. Diuretics: enhanced hypotensive effect, increased risk of first dose hypotensive effect. Moxisylyte: possibly severe postural hypotension when used in combination.

Metabolism

Prazosin is extensively metabolised in the liver, mainly by demethylation and conjugation; some of the metabolites have antihypertensive activity. It is excreted as metabolites and 5-11% as unchanged prazosin mainly in the faeces via the bile.

InChI:InChI=1/C19H21N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h3-4,9-11H,5-8H2,1-2H3,(H2,20,21,22)

Upstream product

• 527-69-5 2-furancarbonyl chloride 
• 60547-97-9 4-amino-6,7-dimethoxy-2-piperazin-1-ylquinazoline 
• 108-86-1 bromobenzene 
• 26961-27-3 2-amino-4,5-dimethoxybenzonitrile 
• 57200-93-8 ethyl 4-(2-furoyl)piperazin-1-ylformimidate hydrochloride 
• 34065-01-5 1-cyanopiperazine 
• 120-43-4 4-ethoxycarbonylpiperazine 
• 23680-84-4 2-chloro-6,7-dimethoxyquinazolin-4-amine 
• 88-14-2 2-furanoic acid 
• 65679-30-3 4-amino-2-(4-ethoxycarbonyl-1-piperazinyl)-6,7-dimethoxy-quinazoline 
• 65679-29-0 4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)-piperazine-1-carbonitrile 
• 1260939-66-9 4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester 

Related news

The effects of Prazosin (cas 19216-56-9) on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis07/30/2019

Nightmares are a highly prevalent and distressing feature of post-traumatic stress disorder (PTSD). Previous studies have reached mixed conclusions regarding the effects of prazosin on nightmares, sleep quality and overall PTSD symptoms in patients with PTSD. MEDLINE, EMBASE, all EBM databases, ...detailed

Relevant articles and documents

PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES

A method of treating cancer in a subject includes administering to the subject a therapeutically effective amount of a compound, the small molecule having a general formula: A-L-X-Z (I).

Targeting Influenza A Virus RNA Promoter

The emergence of drug-resistant strains of influenza virus makes exploring new classes of inhibitors that target universally conserved viral targets a highly important goal. The influenza A viral genome is made up of eight single-stranded RNA-negative segments. The RNA promoter, consisting of the conserved sequences at the 3′ and 5′ end of each RNA genomic segment, is universally conserved among influenza A virus strains and in all segments. Previously, we reported on the identification and NMR structure of DPQ (6,7-dimethoxy-2-(1-piperazinyl)-4-quinazolinamine) (compound 1) in complex with the RNA promoter. Here, we report on additional screening and SAR studies with compound 1, including ex vivo anti-influenza activity assays, resulted in improved cellular activity against influenza A virus in the micromolar range.

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.